Myricx Bio
United KingdomWho owns Myricx Bio?
Myricx Bio is a British Biotech company, now owned by Novartis, which acquired it in 2026 from Sofinnova Partners, Novo Holdings and Abingworth.
Hand-verified · updated 2026-09-30
Open JSON · CC-BY
Key facts
- ·Fully exited in 2026 to Novartis.
- ·Average hold across 3 realized cycles: 3 years.
Ownership history
3 ownership periods · co-invest detected
Sofinnova Partners sold Myricx Bio to Novartis in 2026 after 4 years.
Abingworth sold Myricx Bio to Novartis in 2026 after 2 years.
Novo Holdings sold Myricx Bio to Novartis in 2026 after 2 years.
More from Abingworth Bioventures 8
Other portfolio companies in the same fund.
USMore PE-backed in Biotech
Comparable biotech deals from other GPs.
Questions
Who owns Myricx Bio?
Myricx Bio is now owned by Novartis, which acquired it in 2026 from Sofinnova Partners, Novo Holdings and Abingworth.
When did Novartis acquire Myricx Bio?
Novartis acquired Myricx Bio in 2026, buying from Sofinnova Partners, Novo Holdings and Abingworth.
Who did Myricx Bio sell to?
Sofinnova Partners, Novo Holdings and Abingworth sold Myricx Bio to Novartis in 2026 (Trade Sale).
Who has owned Myricx Bio over time?
Myricx Bio has been through 3 private-equity ownership periods: Sofinnova Partners · via Sofinnova Capital X · 2022–2026 · sold to Novartis · (Trade Sale); Novo Holdings · via Novo Holdings Venture Investments · 2024–2026 · sold to Novartis · (Trade Sale); Abingworth · via Abingworth Bioventures 8 · 2024–2026 · sold to Novartis · (Trade Sale).